1stOncology™: Cancer Intelligence Service – Page 13088 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Diplomat to Release First-Quarter 2019 Operating Results May 7, Participate in Bank of America Merrill Lynch Healthcare Conference May 14

On April 17, 2019 Diplomat Pharmacy, Inc. (NYSE: DPLO), reported that it will release its first-quarter 2019 operating results before market open Tuesday, May 7. A conference call and live webcast will be held at 8:30 a.m. ET (Press release, Diplomat Speciality Pharmacy, APR 17, 2019, View Source [SID1234535182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Shareholders and interested participants can listen to a live broadcast by calling 833.286.5805 (647.689.4450 for international callers) and entering participation code 7747209, starting about 15 minutes before the call. A live webcast of the conference call will be available on the investor relations section of Diplomat’s website at ir.diplomat.is. The site will host an audio recording and supplemental investor information for 90 days.

Diplomat executives Brian Griffin, chairman and CEO, and Dan Davison, chief financial officer, will also participate in the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 14.

Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial

On April 17, 2019 Precision BioSciences (Nasdaq: DTIL) ("Precision"), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, reported it has dosed the first patient in the Phase 1/2a clinical trial of PBCAR0191, its first gene-edited allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate (Press release, Precision Biosciences, APR 17, 2019, View Source [SID1234535181]). Precision is developing PBCAR0191 in collaboration with Servier, an international pharmaceutical company. PBCAR0191 is made from donor-derived T cells that are modified using Precision’s ARCUS genome editing technology. These edits are designed to generate CAR T cells that specifically recognize CD19, an important target in several B-cell cancers, and to prevent graft-versus-host disease, a significant complication associated with existing donor-derived cell-based therapies. This CAR T cell product candidate is being evaluated in adult patients with relapsed or refractory ("R/R") non-Hodgkin lymphoma ("NHL") or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL) as an off-the-shelf cell therapy. The first patient dosed in this trial is being treated for R/R NHL, and Precision believes this is the first U.S.-based clinical trial to evaluate an allogeneic CAR T therapy for NHL.

This multi-center, open label study of PBCAR0191 is expected to enroll up to 80 patients and several dose levels of PBCAR0191 will be investigated. Clinical sites include City of Hope, Moffit Cancer Center, Dana-Farber Cancer Institute and MD Anderson Cancer Center. The primary objective of the trial is to evaluate the safety of PBCAR0191 and determine the maximum tolerated dose. Secondary objectives include evaluating the anti-tumor activity of PBCAR0191. Precision will also evaluate the expansion, trafficking and persistence of PBCAR0191 in treated patients. Lymphodepletion will be conducted several days prior to PBCAR0191 infusion. Patient outcomes will be collected for up to one year.

Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019

On April 17, 2019 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunities for selective cyclin-dependent kinase 7 (CDK7) inhibition in ovarian and breast cancers on Wednesday, April 24, 2019 from 8:30 – 10:30 a.m. ET in New York City (Press release, Syros Pharmaceuticals, APR 17, 2019, View Source [SID1234535180]). Syros is currently evaluating SY-1365, a first-in-class selective CDK7 inhibitor, in a Phase 1 clinical trial as a single agent and in combination with other therapies in multiple ovarian and breast cancer patient populations.

The event will feature presentations from Dejan Juric, M.D., Medical Oncologist and Director at the Termeer Center for Targeted Therapies, Massachusetts General Hospital and Charles A. Leath, III, M.D., M.S.P.H., Professor in the Division of Gynecologic Oncology and Ellen Gregg Shook Culverhouse Chair in Gynecologic Oncology at the University of Alabama Medical Center. Additionally, members of the Syros management team will provide an overview of SY-1365, including preclinical and clinical data supporting its ongoing development in ovarian and breast cancer patients, and SY-5609, its oral selective CDK7 inhibitor, which is expected to enter a Phase 1 oncology study in early 2020.

A live webcast of the event will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following each presentation.

SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer

On April 17, 2019 SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, reported an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC) (Press release, SK biopharmaceuticals, APR 17, 2019, View Source [SID1234535175]).

Under the agreement, twoXAR will use its AI discovery technology to identify a set of initial candidates with the potential to treat lung cancer through novel biological mechanisms of action. After screening, SK Biopharmaceuticals plans to use its internal AI Drug Design technology to optimize a lead candidate and then conduct IND-enabling studies. SK Biopharmaceuticals will retain exclusive worldwide rights to develop and commercialize the drug candidate. twoXAR will receive an upfront payment and will be eligible for development and commercial milestone payments in addition to royalties.

Lung cancer is the leading cause of cancer deaths globally with a 5-year survival rate of less than 18%1. The two main types of lung cancer are small cell and non-small cell, accounting for 10-15% and 85% of all lung cancers, respectively. Treatment is based on the lung cancer stage and subtype, and generally consists of surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments. However, the disease is known to become resistant to current lines of therapy. It is estimated that there were 2 million new lung cancer cases diagnosed worldwide in 20182.

"AI-powered approaches are pioneering new, more efficient ways to find promising new drug candidates and are enabling SK Biopharmaceuticals to build the next-generation pharmaceutical company," said Cheol-Young Maeng, PhD, Vice President of Cancer Research at SK Biopharmaceuticals. "We are excited to combine twoXAR’s and SK Biopharmaceuticals’ technologies because of the potential to progress drug candidates from hypotheses to IND-enabling studies faster than ever before."

"SK Biopharmaceuticals’ focus on powering end-to-end drug discovery and development by adopting new technologies to foster efficiencies makes them an ideal partner for twoXAR," said Andrew A. Radin, Co-Founder and CEO of twoXAR. "As the leading cause of cancer death, lung cancer is a serious disease with high unmet need. We are pleased to be working with SK Biopharmaceuticals, who’s achieved remarkable success from discovery to filing for FDA approval, to combine our complementary platforms with a shared commitment to rapidly identify, validate, and develop novel treatments for lung cancer patients in need."

Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8

On April 17, 2019 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will report its first quarter 2019 financial results on Wednesday, May 8, 2019, after the U.S. financial markets close (Press release, Five Prime Therapeutics, APR 17, 2019, View Source [SID1234535174]). Five Prime will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. (ET) / 1:30 p.m. (PT) to discuss the company’s financial results and provide a general business update.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company’s website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID: 7585986.

The archived conference call will be available on Five Prime’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.